Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.

Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators.

Thromb Haemost. 2019 May;119(5):695-704. doi: 10.1055/s-0039-1679907. Epub 2019 Mar 12.

PMID:
30861548
2.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

3.

Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH.

Casini A, Undas A, Palla R, Thachil J, de Moerloose P; Subcommittee on Factor XIII and Fibrinogen.

J Thromb Haemost. 2018 Sep;16(9):1887-1890. doi: 10.1111/jth.14216. Epub 2018 Aug 3. No abstract available.

PMID:
30076675
4.

Risk factors for inhibitor development in severe hemophilia a.

Garagiola I, Palla R, Peyvandi F.

Thromb Res. 2018 Aug;168:20-27. doi: 10.1016/j.thromres.2018.05.027. Epub 2018 May 25. Review.

PMID:
29879570
5.

Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.

Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM.

Haemophilia. 2018 Jul;24(4):e266-e268. doi: 10.1111/hae.13535. Epub 2018 Jun 5. No abstract available.

PMID:
29869363
6.

Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22. No abstract available.

7.

Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.

Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group.

J Thromb Haemost. 2018 Jan;16(1):39-43. doi: 10.1111/jth.13888. Epub 2017 Nov 16.

8.

Minimal factor XIII activity level to prevent major spontaneous bleeds: reply.

Menegatti M, Palla R, Bucciarelli P, Peyvandi F.

J Thromb Haemost. 2017 Nov;15(11):2280-2282. doi: 10.1111/jth.13851. Epub 2017 Oct 9. No abstract available.

PMID:
28926188
9.

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.

Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F; SIPPET Study Group.

Blood. 2017 Oct 12;130(15):1757-1759. doi: 10.1182/blood-2017-06-791756. Epub 2017 Aug 2.

10.

Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories.

Jennings I, Kitchen S, Menegatti M, Palla R, Walker I, Peyvandi F, Makris M.

Int J Lab Hematol. 2017 Dec;39(6):653-662. doi: 10.1111/ijlh.12721. Epub 2017 Aug 2.

PMID:
28766854
11.

Minimal factor XIII activity level to prevent major spontaneous bleeds.

Menegatti M, Palla R, Boscarino M, Bucciarelli P, Muszbek L, Katona E, Makris M, Peyvandi F; PRO-RBDD study group.

J Thromb Haemost. 2017 Sep;15(9):1728-1736. doi: 10.1111/jth.13772. Epub 2017 Aug 17.

12.

High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15. No abstract available.

13.

Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.

Jennings I, Kitchen S, Menegatti M, Palla R, Walker I, Makris M, Peyvandi F.

Int J Lab Hematol. 2017 Aug;39(4):350-358. doi: 10.1111/ijlh.12633. Epub 2017 Apr 13.

PMID:
28406553
14.

SIPPET: methodology, analysis and generalizability.

Peyvandi F, Mannucci PM, Palla R, Rosendaal FR.

Haemophilia. 2017 May;23(3):353-361. doi: 10.1111/hae.13203. Epub 2017 Mar 17. Review.

PMID:
28306186
15.

Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.

Cannavò A, Valsecchi C, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET study group.

Blood. 2017 Mar 9;129(10):1245-1250. doi: 10.1182/blood-2016-06-720086. Epub 2016 Dec 29. Erratum in: Blood. 2017 Jul 13;130(2):232.

16.

Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders.

Palla R, Siboni SM, Menegatti M, Musallam KM, Peyvandi F; European Network of Rare Bleeding Disorders (EN-RBD) group.

Thromb Res. 2016 Dec;148:128-134. doi: 10.1016/j.thromres.2016.11.008. Epub 2016 Nov 15.

PMID:
27855295
17.

Rare bleeding disorders: diagnosis and treatment.

Palla R, Peyvandi F, Shapiro AD.

Blood. 2015 Mar 26;125(13):2052-61. doi: 10.1182/blood-2014-08-532820. Epub 2015 Feb 23. Review.

18.

FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.

Mancini I, Valsecchi C, Lotta LA, Deforche L, Pontiggia S, Bajetta M, Palla R, Vanhoorelbeke K, Peyvandi F.

Thromb Haemost. 2014 Aug;112(2):297-303. doi: 10.1160/TH13-08-0688. Epub 2014 Apr 17.

PMID:
24740645
19.

A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking.

Menegatti M, Vangone A, Palla R, Milano G, Cavallo L, Oliva R, De Cristofaro R, Peyvandi F.

Thromb Res. 2014 Mar;133(3):481-7. doi: 10.1016/j.thromres.2013.12.020. Epub 2013 Dec 21.

PMID:
24393662
20.

Congenital thrombotic thrombocytopenic purpura with novel mutations in three unrelated Turkish children.

Metin A, Unal S, Gümrük F, Palla R, Cairo A, Underwood M, Gurgey A.

Pediatr Blood Cancer. 2014 Mar;61(3):558-61. doi: 10.1002/pbc.24764. Epub 2013 Sep 30.

PMID:
24115559
21.

Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis.

Vucelić D, Miković D, Rajić Z, Savić N, Budisin Z, Antonijević NM, Obradović S, Jevtić D, Palla R, Valsecchio C, Peyvandi F.

Srp Arh Celok Lek. 2013 Jul-Aug;141(7-8):466-74.

22.

Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management.

Peyvandi F, Menegatti M, Palla R.

Semin Thromb Hemost. 2013 Sep;39(6):579-84. doi: 10.1055/s-0033-1349221. Epub 2013 Jul 25. Review.

PMID:
23888434
23.

Association of β-defensin copy number and psoriasis in three cohorts of European origin.

Stuart PE, Hüffmeier U, Nair RP, Palla R, Tejasvi T, Schalkwijk J, Elder JT, Reis A, Armour JAL.

J Invest Dermatol. 2012 Oct;132(10):2407-2413. doi: 10.1038/jid.2012.191. Epub 2012 Jun 28.

24.

ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.

Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, Mancini I, Musallam KM, Rosendaal FR, Peyvandi F.

J Thromb Haemost. 2012 Aug;10(8):1556-65. doi: 10.1111/j.1538-7836.2012.04808.x.

25.

Divert to ULTRA: differences in infused volumes and clearance in two on-line hemodiafiltration treatments.

Panichi V, De Ferrari G, Saffioti S, Sidoti A, Biagioli M, Bianchi S, Imperiali P, Gabbrielli C, Conti P, Patrone P, Falqui V, Rombolà G, Mura C, Icardi A, Mulas D, Rosati A, Santori F, Mannarino A, Tomei V, Bertucci A, Steckiph D, Palla R.

Int J Artif Organs. 2012 Jun;35(6):435-43. doi: 10.5301/ijao.5000106.

PMID:
22669588
26.

The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.

Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJ, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L.

J Matern Fetal Neonatal Med. 2012 Nov;25(11):2322-5. doi: 10.3109/14767058.2012.694923. Epub 2012 Jun 7.

PMID:
22594569
27.

Measurement of anti-ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays.

Mancini I, Valsecchi C, Palla R, Lotta LA, Peyvandi F.

J Thromb Haemost. 2012 Jul;10(7):1439-42. doi: 10.1111/j.1538-7836.2012.04744.x. No abstract available.

28.

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.

Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolničar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR; European Network of Rare Bleeding Disorders Group.

J Thromb Haemost. 2012 Apr;10(4):615-21. doi: 10.1111/j.1538-7836.2012.04653.x.

29.

B and T lymphocytes in acquired thrombotic thrombocytopenic purpura during disease remission.

Mariani M, Cairo A, Palla R, Lotta LA, Consonni D, Rovati A, Trisolini S, Peyvandi F.

Thromb Res. 2011 Dec;128(6):590-2. doi: 10.1016/j.thromres.2011.07.038. Epub 2011 Aug 27. No abstract available.

PMID:
21872296
30.

Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies.

Palla R, Valsecchi C, Bajetta M, Spreafico M, De Cristofaro R, Peyvandi F.

Thromb Haemost. 2011 Feb;105(2):381-5. doi: 10.1160/TH10-06-0417. Epub 2010 Nov 23. No abstract available.

PMID:
21103662
31.

Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura.

Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, Peyvandi F.

Br J Haematol. 2010 Dec;151(5):488-94. doi: 10.1111/j.1365-2141.2010.08385.x. Epub 2010 Oct 19. Erratum in: Br J Haematol. 2011 Feb;152(3):364.

PMID:
20955397
32.

Measurement methods and accuracy in copy number variation: failure to replicate associations of beta-defensin copy number with Crohn's disease.

Aldhous MC, Abu Bakar S, Prescott NJ, Palla R, Soo K, Mansfield JC, Mathew CG, Satsangi J, Armour JA.

Hum Mol Genet. 2010 Dec 15;19(24):4930-8. doi: 10.1093/hmg/ddq411. Epub 2010 Sep 21.

33.

Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.

Peyvandi F, Palla R, Lotta LA.

Haematologica. 2010 Sep;95(9):1444-7. doi: 10.3324/haematol.2010.027169. No abstract available.

34.

Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.

Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K.

J Thromb Haemost. 2010 Sep;8(9):2053-62. doi: 10.1111/j.1538-7836.2010.03942.x.

35.

Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction.

Peyvandi F, Hollestelle MJ, Palla R, Merlini PA, Feys HB, Vanhoorelbeke K, Lenting PJ, Mannucci PM.

J Thromb Haemost. 2010 Jul;8(7):1653-6. doi: 10.1111/j.1538-7836.2010.03896.x. Epub 2010 Apr 30. No abstract available.

36.

Fibrinogen concentrates.

Peyvandi F, Palla R.

Clin Adv Hematol Oncol. 2009 Dec;7(12):788-90. No abstract available.

PMID:
20332748
37.

ADAMTS-13 assays in thrombotic thrombocytopenic purpura.

Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ.

J Thromb Haemost. 2010 Apr;8(4):631-40. doi: 10.1111/j.1538-7836.2010.03761.x. Epub 2010 Jan 21. Review.

38.

Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress.

Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R.

Free Radic Biol Med. 2010 Feb 1;48(3):446-56. doi: 10.1016/j.freeradbiomed.2009.11.020. Epub 2009 Dec 4.

PMID:
19969076
39.

ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.

Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F.

Hum Mutat. 2010 Jan;31(1):11-9. doi: 10.1002/humu.21143. Review.

PMID:
19847791
40.

Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management.

Peyvandi F, Palla R, Menegatti M, Mannucci PM.

Semin Thromb Hemost. 2009 Jun;35(4):349-55. doi: 10.1055/s-0029-1225757. Epub 2009 Jul 13.

PMID:
19598063
41.

The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, Afrasiabi A, Ramzi M, De Cristofaro R, Peyvandi F.

Haematologica. 2009 Feb;94(2):289-93. doi: 10.3324/haematol.13524. Epub 2008 Dec 30.

42.

Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).

Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lämmle B, de Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM.

J Thromb Haemost. 2008 Sep;6(9):1534-41. doi: 10.1111/j.1538-7836.2008.03099.x. Epub 2008 Jul 26.

43.

Mechanistic studies on ADAMTS13 catalysis.

Di Stasio E, Lancellotti S, Peyvandi F, Palla R, Mannucci PM, De Cristofaro R.

Biophys J. 2008 Sep;95(5):2450-61. doi: 10.1529/biophysj.108.131532. Epub 2008 May 23.

44.

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group.

Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.

PMID:
18305316
45.

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.

Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM.

Haematologica. 2008 Feb;93(2):232-9. doi: 10.3324/haematol.11739. Epub 2008 Jan 26.

46.

Psoriasis is associated with increased beta-defensin genomic copy number.

Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, Reis A, Armour JA, Schalkwijk J.

Nat Genet. 2008 Jan;40(1):23-5. Epub 2007 Dec 2.

47.

[Intravenous immunoglobulins in the treatment of glomerulopathies].

Floccari F, Palla R, Polito P, Campo S, Aloisi C, Buemi M.

G Ital Nefrol. 2007 Jul-Aug;24(4):311-9. Review. Italian.

PMID:
17659502
48.

The Pisa experience of renal biopsies, 1977-2005.

Panichi V, Pasquariello A, Innocenti M, Meola M, Mantuano E, Beati S, Paoletti S, Consani C, Puccini R, Casarosa L, Gattai V, Filippi C, Moriconi L, Barsotti G, Rindi P, Palla R.

J Nephrol. 2007 May-Jun;20(3):329-35.

PMID:
17557266
49.

Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats.

Armour JA, Palla R, Zeeuwen PL, den Heijer M, Schalkwijk J, Hollox EJ.

Nucleic Acids Res. 2007;35(3):e19. Epub 2006 Dec 14.

50.

Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction.

De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM.

J Biol Chem. 2006 Oct 13;281(41):30400-11. Epub 2006 Aug 9.

Supplemental Content

Support Center